AEM vs MEOH

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

MEOH exhibits a severe disconnect between its current market price ($59.75) and its fundamental value, with a Piotroski F-Score of 4/9 indicating only stable health and a Graham Number of $25.71 suggesting significant overvaluation. While the stock has seen a massive 123% 1-year price surge, this is not supported by fundamentals, as YoY EPS growth has plummeted by 111.3% and profit margins have shrunk to a razor-thin 2.22%. The high payout ratio (79.57%) combined with declining earnings creates a risk to dividend sustainability. Despite analyst 'buy' ratings, the deterministic metrics signal a speculative bubble or an over-optimistic anticipation of a cyclical recovery.